ASTRAZENECA is preparing to file for US emergency use authorization (EUA) for its Covid-19 vaccine later this month or early April after accumulating enough data to judge the inoculation's efficacy, sources with knowledge of the ongoing clinical trial told Reuters.
The British drugmaker completed enrollment in its trial of more than 32,000 volunteers in January and now has data on at least 150 cases of Covid-19, said two sources familiar with the trial.
The number of Covid-19 cases among those who got the vaccine versus infections in participants who received a placebo will show how effective the AstraZeneca shot was at preventing illness in those age 18 and over.
The AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorised for use in the EU and many countries but not yet by US regulators.
"The US Phase III study results are necessary for the FDA’s evaluation of an EUA request for our vaccine," a company spokeswoman said, without confirming trial details.
"We expect data from our U.S. Phase III trial to be available soon, in the coming weeks, and we plan to file for emergency use authorisation shortly thereafter."
Highly anticipated results from the US trial could help settle safety concerns arising over reports of serious blood clots in some vaccine recipients that have led several nations to pause administering the vaccine.
A World Health Organization expert advisory committee is looking into the matter.
The data could also help determine what becomes of doses already sitting in US warehouses awaiting approval. The New York Times reported on Thursday (11) that some countries have been asking to procure doses of the vaccine not currently being offered in the US.
AstraZeneca said in February it expects its vaccine could receive US emergency use authorisation at the beginning of April and could immediately deliver 30 million doses to locations around the US.
In a Friday (12) press briefing, White House Coronavirus Response Coordinator Jeff Zients said the US has a small inventory of the AstraZeneca vaccine, which it plans to keep and deploy to Americans should an EUA be granted.
The US stance could thwart AstraZeneca’s efforts to come closer to delivering on its contractual obligation with the EU of 180 million doses in the second quarter.
AstraZeneca told the EU earlier this year it would cut its supplies in the second quarter by at least half to less than 90 million doses, EU sources said, after a bigger reduction in the first three months of the year.
